Summary
Edwards Lifesciences Corporation (EW) announced a significant settlement with Abbott Laboratories on July 13, 2020, to resolve all ongoing patent disputes related to transcatheter mitral and tricuspid repair products. This agreement aims to end costly legal battles and allow both companies to focus on innovation and market growth in the critical heart valve repair sector. While the settlement brings clarity and mitigates future legal risks, it comes with an immediate financial impact. Edwards Lifesciences will recognize a pretax charge of approximately $368 million in the second quarter of 2020. Additionally, the company anticipates incurring royalty expenses totaling around $100 million through May 2024, which will be recorded as a cost of sales. Investors should monitor how these charges affect near-term profitability and the company's cost structure.
Key Highlights
- 1Settlement reached with Abbott Laboratories to resolve all patent disputes concerning transcatheter mitral and tricuspid repair products.
- 2Agreement aims to end ongoing legal disputes and provide greater certainty in the market.
- 3Edwards Lifesciences will record a pretax charge of approximately $368 million in Q2 2020 related to the settlement.
- 4Royalty expenses of approximately $100 million are expected through May 2024.
- 5These royalty expenses will be classified as a cost of sales.
- 6The settlement is expected to reduce future litigation-related expenses and risks.
- 7The press release is furnished as an exhibit to the 8-K filing.